When togive H2RAswithdasatinibModerateto highemetogenicrisk TKIsI want toavoid thisTKI if I donot wantdiarrheaTherecommendedcriteria usedfor acceleratedphaseThis TKI hasthe mostmetabolicsyndromeAfter 3months, I have3% BCR-ABL,I have this TKIresponseTreatmentfor blastphaseCMLTKIs aremajorsubstratesfor this liverenzymeThe current5-yearoverallsurvival rateof CMLI have theT315I mutationbut also haveelevated lipaseDrug classthatrevolutionizedCMLtreatmentI failed 3lines of TKIs,I can try thisagent nextThe scoringsystem usedin chronicphaseTranslocationbetweenthese twochromosomesoccur in CMLPatients havepresence of thisBCR-ABLproteinindicative ofCML I avoid thisdrug classwith bosutinib,nilotinib anddasatinibThelandmarkfor thefirst TKI60-70% ofpatients withCML presentwith thissymptomThe numberof distinctclinicalphases inCMLResponsewhen BCR-ABL1 (IS)is <0.01%Number ofblastspresent inacceleratedphasePercentageof blastspresent inthe blastphaseNon-pharmacologicaltreatment forCMLToo many ofthese bloodcells areabnormal inCMLWhen togive H2RAswithdasatinibModerateto highemetogenicrisk TKIsI want toavoid thisTKI if I donot wantdiarrheaTherecommendedcriteria usedfor acceleratedphaseThis TKI hasthe mostmetabolicsyndromeAfter 3months, I have3% BCR-ABL,I have this TKIresponseTreatmentfor blastphaseCMLTKIs aremajorsubstratesfor this liverenzymeThe current5-yearoverallsurvival rateof CMLI have theT315I mutationbut also haveelevated lipaseDrug classthatrevolutionizedCMLtreatmentI failed 3lines of TKIs,I can try thisagent nextThe scoringsystem usedin chronicphaseTranslocationbetweenthese twochromosomesoccur in CMLPatients havepresence of thisBCR-ABLproteinindicative ofCML I avoid thisdrug classwith bosutinib,nilotinib anddasatinibThelandmarkfor thefirst TKI60-70% ofpatients withCML presentwith thissymptomThe numberof distinctclinicalphases inCMLResponsewhen BCR-ABL1 (IS)is <0.01%Number ofblastspresent inacceleratedphasePercentageof blastspresent inthe blastphaseNon-pharmacologicaltreatment forCMLToo many ofthese bloodcells areabnormal inCML

Chronic Myeloid Leukemia BINGO - Call List

(Print) Use this randomly generated list as your call list when playing the game. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
G
2
G
3
B
4
N
5
O
6
I
7
I
8
I
9
I
10
N
11
N
12
O
13
B
14
G
15
B
16
I
17
G
18
G
19
O
20
B
21
O
22
B
23
O
24
N
  1. G-When to give H2RAs with dasatinib
  2. G-Moderate to high emetogenic risk TKIs
  3. B-I want to avoid this TKI if I do not want diarrhea
  4. N-The recommended criteria used for accelerated phase
  5. O-This TKI has the most metabolic syndrome
  6. I-After 3 months, I have 3% BCR-ABL, I have this TKI response
  7. I-Treatment for blast phase CML
  8. I-TKIs are major substrates for this liver enzyme
  9. I-The current 5-year overall survival rate of CML
  10. N-I have the T315I mutation but also have elevated lipase
  11. N-Drug class that revolutionized CML treatment
  12. O-I failed 3 lines of TKIs, I can try this agent next
  13. B-The scoring system used in chronic phase
  14. G-Translocation between these two chromosomes occur in CML
  15. B-Patients have presence of this BCR-ABL protein indicative of CML
  16. I-I avoid this drug class with bosutinib, nilotinib and dasatinib
  17. G-The landmark for the first TKI
  18. G-60-70% of patients with CML present with this symptom
  19. O-The number of distinct clinical phases in CML
  20. B-Response when BCR-ABL1 (IS) is <0.01%
  21. O-Number of blasts present in accelerated phase
  22. B-Percentage of blasts present in the blast phase
  23. O-Non-pharmacological treatment for CML
  24. N-Too many of these blood cells are abnormal in CML